SiMoA
UltraDx Bio Receives Chinese Clinical Registration Approval for UD-X Immunoassay Analyzer
With the approval, the UD-X analyzer, which uses Quanterix's single-molecule array technology, can be used for clinical applications in China.
The company reported a 4 percent decline in Q3 revenues and a 30 percent drop in consumables revenue while addressing issues with assay quality control.
In a study published this week, researchers presented a Simoa-based assay for tuberculosis that could ultimately be packaged as a point-of-care test.
Quanterix Q1 Revenues Up 64 Percent
The company posted Q1 revenues of $12.3 million, up from $7.5 million in Q1 2018 and above the consensus Wall Street estimate of $10.2 million.
Quanterix Ends IVD Agreement With BioMérieux
By ending the agreement, Quanterix regains full control over its Simoa immunoassay technology and its potential use for in vitro diagnostic purposes.